Drug Resistance Analysis of Mycoplasma Pneumonia in Wuxi Region From 2021 to 2023
Objective To retrospectively analyze drug resistance of Mycoplasma pneumonia in adults with respiratory tract infections in Wuxi region from January 2021 to November 2023,and provide information for infection therapy.Methods Drug resistance of 104 strains of mycoplasma pneumonia from the respiratory tract of adult patients to 14 antimicrobial drugs used for treatment was retrospectively analyzed from January 2021 to November 2023 in Wuxi Branch,Ruijin Hospital,Shanghai Jiao Tong University School of Medicine.Results Mycoplasma pneumonia showed a high rate of resistance to some of the commonly prescribed antimicrobial drugs:acetylspiramycin(54.8%,57 strains),moxifloxacin(43.3%,45 strains),doxycycline(32.7%,34 strains),minocycline(25.0%,26 strains),ciprofloxacin(15.4%,16 strains),clindamycin l(13.5%,14 strains),a low rate of resistance to other commonly prescribed antimicrobial drugs such as erythromycin,gatifloxacin,josamycin,levofloxacin,azithromycin,clarithromycin,erythromycin,and roxithromycin(less than 9 strains).Conclusion Respiratory tract infections with Mycoplasma pneumoniae in adult should be treated with macrolides and quinolones,but but acetylspiramycin(a macrolide)and moxifloxacin and ciprofloxacin(quinolones)should be avoided.
NETL
NSTL
万方数据
